Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.

Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M.

Vaccine. 2011 Jan 17;29(4):644-9. doi: 10.1016/j.vaccine.2010.11.043. Epub 2010 Dec 4.

PMID:
21134451
2.

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G.

Vaccine. 2013 Feb 18;31(9):1298-304. doi: 10.1016/j.vaccine.2012.12.076. Epub 2013 Jan 9.

3.

Chitosan as an adjuvant for poliovaccine.

Ghendon Y, Markushin S, Akopova I, Koptiaeva I, Krivtsov G.

J Med Virol. 2011 May;83(5):847-52. doi: 10.1002/jmv.22030.

PMID:
21412793
4.

[Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].

Gendon IuZ, Markushin SG, Akopova II, Krivtsov GG, Akhmatova NK, Koptiaeva IB, Vasil'ev IuM.

Vopr Virusol. 2011 Nov-Dec;56(6):28-32. Russian.

PMID:
22359946
5.

Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.

Westdijk J, Brugmans D, Martin J, van't Oever A, Bakker WA, Levels L, Kersten G.

Vaccine. 2011 Apr 18;29(18):3390-7. doi: 10.1016/j.vaccine.2011.02.085. Epub 2011 Mar 11.

PMID:
21397718
6.

Polio vaccination: past, present and future.

Bandyopadhyay AS, Garon J, Seib K, Orenstein WA.

Future Microbiol. 2015;10(5):791-808. doi: 10.2217/fmb.15.19. Epub 2015 Mar 31. Review.

7.

Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle.

Romera SA, Hilgers LA, Puntel M, Zamorano PI, Alcon VL, Dus Santos MJ, Blanco Viera J, Borca MV, Sadir AM.

Vaccine. 2000 Aug 15;19(1):132-41.

PMID:
10924795
8.

Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.

Andreasen LV, Hansen LB, Andersen P, Agger EM, Dietrich J.

Vaccine. 2015 Apr 8;33(15):1873-9. doi: 10.1016/j.vaccine.2015.02.011. Epub 2015 Feb 17.

PMID:
25698487
9.

Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice.

Wang RN, Wang YB, Geng JW, Guo DH, Liu F, Chen HY, Zhang HY, Cui BA, Wei ZY.

Vaccine. 2012 Jul 27;30(35):5246-52. doi: 10.1016/j.vaccine.2012.05.077. Epub 2012 Jun 13.

PMID:
22705080
10.

A survey for neutralizing antibodies to the three types of poliovirus among children in Maiduguri, Nigeria.

Baba MM, Haruna BA, Ogunmola O, Ambe JP, Shidali NN, Oderinde B, Marcello A, Talle M.

J Med Virol. 2012 Apr;84(4):691-6. doi: 10.1002/jmv.23228.

PMID:
22337311
11.
12.

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.

Yang C, Shi H, Zhou J, Liang Y, Xu H.

Vaccine. 2009 Nov 5;27(47):6558-63. doi: 10.1016/j.vaccine.2009.08.047. Epub 2009 Sep 1.

PMID:
19729087
13.

A mucosal adjuvant for the inactivated poliovirus vaccine.

Steil BP, Jorquera P, Westdijk J, Bakker WA, Johnston RE, Barro M.

Vaccine. 2014 Jan 23;32(5):558-63. doi: 10.1016/j.vaccine.2013.11.101. Epub 2013 Dec 13.

14.

Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.

Wu J, Wang F, Fang F, Zhang W, Chang H, Zheng L, Chen Z.

Arch Virol. 2011 Mar;156(3):387-95. doi: 10.1007/s00705-010-0860-4. Epub 2010 Nov 26.

PMID:
21110049
15.

Alternative delivery of a thermostable inactivated polio vaccine.

Kraan H, Ploemen I, van de Wijdeven G, Que I, Löwik C, Kersten G, Amorij JP.

Vaccine. 2015 Apr 21;33(17):2030-7. doi: 10.1016/j.vaccine.2015.03.011. Epub 2015 Mar 13.

16.

Switching from OPV to IPV: are we behind the schedule in Latin America?

Salas-Peraza D, Avila-Agüero ML, Morice-Trejos A.

Expert Rev Vaccines. 2010 May;9(5):475-83. doi: 10.1586/erv.10.39. Review.

PMID:
20450322
17.

Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.

Maves RC, Castillo Oré RM, Porter KR, Kochel TJ.

Clin Vaccine Immunol. 2010 Feb;17(2):304-6. doi: 10.1128/CVI.00353-09. Epub 2009 Dec 9.

18.

Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Dietrich J, Andreasen LV, Andersen P, Agger EM.

PLoS One. 2014 Jun 23;9(6):e100879. doi: 10.1371/journal.pone.0100879. eCollection 2014.

19.

Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.

Taffs RE, Chernokhvostova YV, Dragunsky EM, Nomura T, Hioki K, Beuvery EC, Fitzgerald EA, Levenbook IS, Asher DM.

J Infect Dis. 1997 Feb;175(2):441-4.

20.

Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.

Rennels MB, Englund JA, Bernstein DI, Losonsky GA, Anderson EL, Pichichero ME, Munoz FM, Wolff MC.

Pediatr Infect Dis J. 2000 May;19(5):417-23.

PMID:
10819337
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk